1. Home
  2. PCRX vs CNMD Comparison

PCRX vs CNMD Comparison

Compare PCRX & CNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

N/A

Current Price

$25.41

Market Cap

999.0M

Sector

Health Care

ML Signal

N/A

Logo CONMED Corporation

CNMD

CONMED Corporation

N/A

Current Price

$49.17

Market Cap

985.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCRX
CNMD
Founded
2006
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
999.0M
985.5M
IPO Year
2010
1995

Fundamental Metrics

Financial Performance
Metric
PCRX
CNMD
Price
$25.41
$49.17
Analyst Decision
Strong Buy
Hold
Analyst Count
4
5
Target Price
$30.25
$46.25
AVG Volume (30 Days)
642.3K
734.0K
Earning Date
04-30-2026
04-29-2026
Dividend Yield
N/A
1.11%
EPS Growth
107.44
N/A
EPS
0.19
1.22
Revenue
$541,533,000.00
$1,374,724,000.00
Revenue This Year
$6.78
$0.82
Revenue Next Year
$8.54
$5.48
P/E Ratio
$131.68
$40.26
Revenue Growth
26.04
5.18
52 Week Low
$18.80
$31.44
52 Week High
$27.66
$56.64

Technical Indicators

Market Signals
Indicator
PCRX
CNMD
Relative Strength Index (RSI) 44.73 64.63
Support Level $24.61 $40.14
Resistance Level $26.94 $53.66
Average True Range (ATR) 1.00 2.10
MACD -0.25 0.25
Stochastic Oscillator 18.84 63.63

Price Performance

Historical Comparison
PCRX
CNMD

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About CNMD CONMED Corporation

Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.

Share on Social Networks: